Immunomedics, Inc. (NASDAQ: IMMU) today announced that the Company plans to initiate a Phase 2 pivotal TROPHY U-01 study of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Immunomedics (IMMU) & Clovis Oncology (CLVS) Report Planned Clinical Collaboration to Study Combination Therapies June 4, 2018 6:18 AM Immunomedics Announces Pivotal Study of Sacituzumab Govitecan in Patients With Locally Advanced or Metastatic Urothelial CancerJune 1, 2018 8:00 AM